Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05747794 · ClinicalTrials.gov registry record · Phase 2
Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination with Paclitaxel Chemotherapy
A Phase 2 study of Breast Carcinoma, sponsored by Immutep S.A.S..
- Active
- Registry status
- Phase 2
- Development phase
- 849
- Enrollment target
- 20
- Study locations
NCT05747794 is a Phase 2 study of Breast Carcinoma that is active but no longer recruiting, run by Immutep S.A.S.. The registered enrollment target is 849 participants, above the 762-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (11% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT05747794, a Phase 2 study of Breast Carcinoma, is active but no longer recruiting, sponsored by Immutep S.A.S..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 849 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to compare the safety and efficacy of eftilagimod alpha (efti) in combination with paclitaxel standard of care chemotherapy in participants with metastatic breast cancer. The main questions it aims to answer are: * What is the optimal biological dose (OBD) of efti in combination with weekly paclitaxel chemotherapy? * Can efti combined with weekly paclitaxel chemotherapy prolong overall survival in participants with metastatic breast cancer if compared to weekly paclitaxel chemotherapy alone? In the first component of the trial (phase 2, lead-in) researchers will compare two groups (different dose levels of efti in combination with standard chemotherapy) to see if the treatment is safe and well tolerated and evaluate which is the optimal biological dose. In the second component of the trial (phase 3) researchers will assess if the treatment of metastatic breast cancer with the optimal biological dose of efti in combination with paclitaxel is superior compared to chemotherapy alone (placebo-controlled). The treatment concept of each trial component consists of a chemo-immunotherapy phase followed by an immunotherapy phase. In the first phase participants will be treated with efti plus paclitaxel chemotherapy or placebo plus paclitaxel chemotherapy. After completion of the chemotherapy per standard of care, participants will be treated with the study agent alone.
Conditions Studied
Interventions
- DRUG Paclitaxel
- OTHER placebo
- BIOLOGICAL eftilagimod alpha
Study Locations (20)
Other
- AZ Sint-Jan Brugge Oostende av - Bruges
- Cliniques Universitaires Saint-Luc - Brussels
- Grand Hopital de Charleroi - Hopital Notre Dame - Charleroi
- Universitair Ziekenhuizen Antwerpen - Edegem
- Centre Hospitalier de l'Ardenne - Libramont
- Clinique Saint-Pierre- Ottignies - Ottignies-Louvain-la-Neuve
- ARENSIA Exploratory Medicine LLC - Tbilisi
- ARENSIA Exploratory Medicine Phase I Unit - Chisinau
- Institut Català d'Oncologia - Badalona
- VHIO - Hospital Vall d'Hebron - Barcelona
- Hospital Clinic de Barcelona - Barcelona
- Parc Taulí Hospital Universitari - Barcelona
- Hospital Universitario Reina Sofia - Córdoba
- Hospital Universitario de Jaén - Jaén
- Unidad Ensayos Clínicos Oncología Fundació IRB Lleida - Lleida
Texas
- Oncology Consultants - Houston
- The University of Texas MD Anderson Cancer Center - Houston
California
- The Oncology Institute - Whittier
District of Columbia
- The George Washington University Cancer Center - Washington D.C.
South Carolina
- Carolina Blood and Cancer Care Associates - Rock Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 849 participants |
| Start Date | 2023-05-22 |
| Est. Completion | 2027-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05747794
The ClinicalTrials.gov registry entry for NCT05747794 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 849 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 762-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (11% higher). The listed sponsor is Immutep S.A.S., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Paclitaxel is the first listed.
NCT05747794 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT05747794 about?
NCT05747794 is a clinical study titled "Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination with Paclitaxel Chemotherapy". The goal of this clinical trial is to compare the safety and efficacy of eftilagimod alpha (efti) in combination with paclitaxel standard of care chemotherapy in participants with metastatic breast cancer. The main questions it aims to answer are: * What is the optimal biological dose (OBD) of eft...
What is the current status of trial NCT05747794?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 849 participants. The study started on 2023-05-22. Estimated completion is 2027-07-31.
What conditions does trial NCT05747794 study?
This clinical trial studies the following conditions: Breast Carcinoma.
What interventions are being tested in trial NCT05747794?
The interventions under investigation include: Paclitaxel (DRUG), placebo (OTHER), eftilagimod alpha (BIOLOGICAL).
Who is sponsoring clinical trial NCT05747794?
This trial is sponsored by Immutep S.A.S., which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05747794 being conducted?
This trial has 20 study locations across California, District of Columbia, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
RECRUITING · Phase 2
-
Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
RECRUITING · Phase 2
-
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
RECRUITING · Phase 2
-
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
RECRUITING · Phase 2
-
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
RECRUITING · Phase 2
-
Study of Aerobic Training for People Receiving Chemotherapy for Breast Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.